<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <iati-identifier>SE-0-SE-29-2013-6727-287-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Tools to study the effects of rotavirus vaccination in Burkina Faso</narrative>
   <narrative xml:lang="SV">Verktyg f&#xF6;r att studera effekterna av rotavirusvaccination i Burkina Faso</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">Diarrhea is a major global health issue in children, and heavily affects sub-Saharan Africa. Rotavirus is the major cause for severe childhood diarrhea, thus rotavirus vaccines are an important preventive measure of diarrhea. Vaccine trials have, however, showed a reduced vaccine efficacy in many African countries. Burkina Faso is now about to implement vaccination nationwide and our research proposal is centered on this. By closely monitoring rotavirus before; during and after national immunization, we can investigate factors important for vaccine efficacy. A first objective is to establish RV surveillance logistics and techniques before vaccination. We have performed preliminary studies and found many unusual strains which could influence vaccine efficacy. The major objective is to determine the vaccine efficacy and relate this to evolving escape mutants and specific strains present in Burkina Faso. Our third scientific approach is most novel and based on preliminary data from Burkina Faso observing that children with the Lewis-negative phenotype, common in Burkina Faso, where not infected with vaccine-like strains, providing an explanation for reduced vaccine efficacy in Africa. The overall objective of this collaboration is increased knowledge and better techniques to study RV and factors important for successful vaccination; which will be done through regular workshops, lectures and scientific visits by researchers from Sweden and Burkina Faso.</narrative>
   <narrative xml:lang="SV">Vilka faktorer p&#xE5;verkar skyddet av rotavirusvaccination av barn i Burkina Faso? Akuta diarr&#xE9;sjukdomar &#xE4;r fortfarande ett av de fr&#xE4;msta globala h&#xE4;lsoproblemen och orsakar n&#xE4;stan en femtedel av alla d&#xF6;dsfall bland yngre barn i utvecklingsl&#xE4;nder. Rotavirus &#xE4;r den vanligaste orsaken till akut och allvarlig diarr&#xE9; hos barn och orsakar ca en halv miljon d&#xF6;dsfall per &#xE5;r. Eftersom f&#xF6;rb&#xE4;ttrad sanitet och hygien har begr&#xE4;nsad effekt p&#xE5; sjukdomsspridning anses rotavirusvaccination vara det viktigaste s&#xE4;ttet att minska d&#xF6;dligheten i h&#xE5;rt drabbade l&#xE4;nder. Vaccinen rekommenderas av WHO och andra h&#xE4;lsoorganisationer men flera studier har visat p&#xE5; att vaccinen inte &#xE4;r lika effektiva i utvecklingsl&#xE4;nder, framf&#xF6;rallt i Afrika. Sk&#xE4;len till den l&#xE5;ga effektiviteten &#xE4;r &#xE4;nnu inte fastst&#xE4;llda men n&#xE5;gra anledningar kan vara undern&#xE4;ring, f&#xF6;rekomst av andra sjukdomar, samt cirkulation av ovanliga rotavirusstammar mot vilka vaccinen inte skyddar. Burkina Faso, ett land i V&#xE4;stafrika med mycket h&#xF6;g barnad&#xF6;dlighet, planerar nu att inf&#xF6;ra rotavirusvaccination under senare delen av 2014. I detta projekt vill vi i n&#xE4;ra samarbete Dr. Isidore Bonkoudougou vid nationella folkh&#xE4;lsoinstitutet i Ouagadougou, Burkina Faso p&#xE5; n&#xE4;ra h&#xE5;ll f&#xF6;lja effekterna av vaccinationen. Genom dessa studier har vi en unik m&#xF6;jlighet att unders&#xF6;ka vilka faktorer som p&#xE5;verkar hur bra vaccinen fungerar. Vi kommer att i f&#xF6;rsta skedet (projekt 1) etablera tekniker och metoder f&#xF6;r att unders&#xF6;ka rotavirusf&#xF6;rekomst och vilka stammar som cirkulerar i Burkina Faso innan vaccination b&#xF6;rjar. Under och efter vaccinationen (projekt 2) kommer vi sedan unders&#xF6;ka effektiviten av vaccinet och om vaccinet skyddar mot de rotavirusstammar som finns i Burkina Faso. Vi kommer &#xE4;ven med molekyl&#xE4;rbiologiska tekniker &#xF6;vervaka om nya muterade rotavirus uppkommer mot vilket vaccinet inte skyddar. Slutligen har vi genom tidigare studier i Burkina Faso utvecklat en hypotes om att det finns genetiska faktorer hos en tredjedel av populationen som g&#xF6;r dem mindre mottagliga f&#xF6;r vaccinet. Vi kommer s&#xE5;ledes (projekt 3) unders&#xF6;ka om de barn som inte blir skyddade av vaccinen har denna genetiska faktor. Detta projekt &#xE4;r vetenskapligt helt nytt och kan leda till att nya och b&#xE4;ttre vaccin utvecklas b&#xE4;ttre anpassade f&#xF6;r utsatta populationer. Genom att anordna workshops, seminarier samt f&#xF6;rel&#xE4;sningar ska metoder, teknik och kunskap &#xF6;verf&#xF6;ras till samarbetspartners i Burkina Faso. Detta &#xE4;r speciellt viktigt i detta skede s&#xE5; att de n&#xF6;dv&#xE4;ndiga vetenskapliga redskapen finns p&#xE5; plats innan vaccineringen b&#xF6;rjar. V&#xE5;rt &#xF6;vergripande m&#xE5;l &#xE4;r att genom kontinuerligt samarbete med forskare i Burkina Faso st&#xE4;rka kunskapsbasen inom virologi och vaccination med huvudfokus p&#xE5; rotavirus och andra diarr&#xE9;sjukdomar.</narrative>
  </description>
  <participating-org ref="51000" role="4" type="80">
   <narrative xml:lang="EN">Link&#xF6;pings universitet</narrative>
  </participating-org>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-29" role="3" type="10">
   <narrative xml:lang="EN">The Swedish Research Council</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2014-01-01" type="2"></activity-date>
  <activity-date iso-date="2016-12-31" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">The Swedish Research Council</narrative>
   </organisation>
   <telephone>+46 8 546 44 000</telephone>
   <email>vetenskapsradet@vr.se</email>
   <website>www.vr.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Box 1035, 101 38 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="BF" percentage="100">
   <narrative xml:lang="EN">Burkina Faso</narrative>
  </recipient-country>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="D02" vocabulary="1"></default-aid-type>
  <default-tied-status code="4"></default-tied-status>
  <budget>
   <period-start iso-date="2014-01-01"></period-start>
   <period-end iso-date="2014-12-28"></period-end>
   <value currency="USD" value-date="2014-01-01">36152.1304975291</value>
  </budget>
  <budget>
   <period-start iso-date="2015-01-01"></period-start>
   <period-end iso-date="2015-12-28"></period-end>
   <value currency="USD" value-date="2015-01-01">23608.1287888674</value>
  </budget>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">25243.9665751183</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2013-01-01"></transaction-date>
   <value currency="USD" value-date="2013-01-01">101793.2813363631</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2014-01-28"></transaction-date>
   <value currency="USD" value-date="2014-01-28">36152.1304975291</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2015-01-28"></transaction-date>
   <value currency="USD" value-date="2015-01-28">23607.6542536154</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-01-28"></transaction-date>
   <value currency="USD" value-date="2016-01-28">25243.9665751183</value>
  </transaction>
  <crs-add>
   <other-flags code="1" significance="1"></other-flags>
  </crs-add>
  <contribution contributionid="2013-6727" xmlns="http://sida.se/ns/contribution#"></contribution>
 </iati-activity>
</iati-activities>
